New, oral LHRH antagonists in treatment of prostate cancer?

At least three new LHRH receptor antagonists — i.e., drugs similar to degarelix (Firmagon) — are in development at the present time: elagolix, relugolix, and ASP-1707. However, unlike degarelix, all three are agents that would act as oral drugs as opposed to drugs one has to be given as long-term injections.

At present, these drugs are also all in initial development for the treatment o fendometriosis in women, and not for treatment of prostate cancer … but then that’s what originally happened with the early development of drugs like leuprolide actetate (Lupron) and the other LHRH agonists back in the 1980s too.

Read more at The NEW Prostate Cancer Infolink

Translate »